Table 2.
Antimicrobial susceptibility among 1764 Salmonella enterica isolates from humans with infections in Guangdong province, China, during 2007 and 2012, and MDR in each of the top 11 serovars
| |
|
No. of isolates resistant to indicated agent at the indicated breakpoint (% resistance)
a
|
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. enterica serovar | No. of isolates | AMP Ampicillin | CAZ Ceftazidime | CTX Cefotaxime | FEP Cefepime | NAL Nalidixic acid | CIP Ciprofloxacin | SMX Sulfamethoxazole | TMP Trimethoprim | TCY Tetracycline | GEN Gentamicin | STR Streptomycin | CHL Chloramphenicol | MDR |
| Enteritidis |
257 |
143(55.64) |
11(4.28) |
14(5.45) |
18(7.01) |
212(82.49) |
11(4.28) |
141(54.86) |
23(89.49) |
76(29.57) |
23(8.95) |
110(42.81) |
10(3.89) |
116(45.14) |
| Typhimurium |
523 |
453(86.62) |
43(82.21) |
68(13.01) |
69(13.19) |
437(83.56) |
60(11.47) |
455(86.99) |
337(64.44) |
457(87.38) |
340(65.01) |
391(74.76) |
381(72.85) |
454(86.80) |
| 1,4,5,12:i:- |
244 |
220(90.16) |
18(7.37) |
30(12.29) |
29(11.88) |
182(74.59) |
28(11.47) |
220(90.16) |
128(52.46) |
228(93.44) |
141(57.78) |
164(67.21) |
164(67.21) |
218(89.34) |
| Stanley |
167 |
14(8.38) |
10(5.99) |
11(6.58) |
9(5.39) |
19(11.37) |
8(4.79) |
35(20.96) |
14(8.38) |
20(11.98) |
13(7.78) |
25(14.97) |
13(7.78) |
18(10.78) |
| Derby |
46 |
15(26.08) |
2(4.35) |
3(6.52) |
3(6.52) |
17(36.96) |
4(8.69) |
35(76.08) |
14(30.44) |
22(47.83) |
14(30.44) |
19(41.30) |
16(34.78) |
15(32.61) |
| Rissen |
36 |
26(72.22) |
3(8.33) |
5(13.89) |
6(16.67) |
5(13.89) |
1(2.78) |
23(63.89) |
30(83.33) |
31(86.11) |
7(19.44) |
16(44.44) |
5(13.89) |
15(41.67) |
| Weltevreden |
35 |
3(8.57) |
2(5.71) |
2(5.71) |
2(5.71) |
4(11.43) |
1(2.86) |
8(22.86) |
4(11.43) |
6(17.14) |
3(8.57) |
6(17.14) |
2(5.71) |
3(8.57) |
| Infantis |
28 |
23(82.14) |
0 |
3(10.71) |
2(7.14) |
23(82.14) |
0 |
23(82.14) |
19(67.86) |
19(67.86) |
4(14.28) |
4(14.28) |
21(75) |
21(75) |
| Agona |
24 |
4(16.67) |
0 |
1(4.17) |
3(12.5) |
4(16.67) |
3(12.5) |
7(29.17) |
3(12.5) |
8(33.33) |
4(16.67) |
5(20.83) |
5(20.83) |
6(25) |
| Albany |
22 |
21(95.45) |
3(13.63) |
4(18.18) |
4(18.18) |
20(90.9) |
1(4.54) |
22(100) |
20(90.9) |
21(95.45) |
4(18.18) |
7(31.81) |
21(95.45) |
20(90.9) |
| Newport |
19 |
3(15.79) |
2(10.53) |
1(5.26) |
0 |
4(21.05) |
1(5.26) |
5(26.31) |
3(15.79) |
6(31.57) |
2(10.53) |
5(26.31) |
3(15.79) |
4(21.05) |
| Typhi |
4 |
1(25) |
0 |
1(25) |
0 |
1(25) |
0 |
1(25) |
1(25) |
1(25) |
1(25) |
1(25) |
1(25) |
1(25) |
| Paratyphi (A + B + C) |
24 |
5(20.83) |
2(8.33) |
1(4.16) |
1(4.16) |
5(20.83) |
1(4.16) |
4(16.66) |
0 |
2(8.33) |
1(4.16) |
4(16.66) |
0 |
3(12.5) |
| Other 114 NTS serovars |
335 |
106(31.64) |
28(8.35) |
32(9.55) |
23(6.86) |
119(35.52) |
23(6.86) |
141(42.09) |
106(31.06) |
161(31.64) |
54(16.11) |
121(36.11) |
72(21.49) |
103(30.74) |
| Total (% resistance)b | 1037(58.78) | 124(7.03) | 176(9.98) | 169(9.58) | 1052(59.64) | 142(8.05) | 1120(63.49) | 702(39.79) | 1058(59.97) | 611(34.64) | 878(49.77) | 714(40.48) | 997(56.52) | |
aThe percentage means the proportion of MDR isolates within each serotype.
bThe percentage means the proportion of MDR isolates in total 1764 isolates.